Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan

Background: Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatini...

Full description

Saved in:
Bibliographic Details
Main Authors: Jerry Shu-Hung Kuo, Cheng-Yu Chang, Shih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Current Oncology
Subjects:
Afatinib
Osimertinib
EGFR mutation
lung cancer
rebiopsy
Online Access:https://www.mdpi.com/1718-7729/32/1/36
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items